Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis
Surgery, Postoperative Blood Loss
About this trial
This is an interventional prevention trial for Surgery
Eligibility Criteria
Inclusion Criteria: Adults at least 18 years of age who elect to undergo cosmetic or functional open primary rhinoplasty with osteotomies (repositioning the nasal bones) by Drs. Yang or Patel at VUMC. No other facial plastics procedure nor sinus surgery performed simultaneously Lack all the below Exclusion Criteria Exclusion Criteria: Known allergy to TXA (tranexamic acid) Intracranial bleeding Known defective color vision History of venous or arterial thromboembolism Active thromboembolic disease Severe renal impairment (diagnosis of chronic kidney disease) History of coagulation disorder Known thrombocytopenia (platelets <150,000) Current use of anticoagulant (blood thinner) Uncontrolled DM (diabetes mellitus) preventing use of dexamethasone in the perioperative period Cardiac arrhythmia History of AMI (acute myocardial infarction), stroke, seizure, liver failure Laboratory results showing platelets <150,000, PT (prothrombin time) >45, INR (international normalized ratio) >1.2, seizure disorder
Sites / Locations
- Vanderbilt University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Tranexamic Acid
Control
Patients receive 1 gram IV tranexamic acid in the operating room prior to surgical incision.
Routine care, no tranexamic acid given.